Trial Profile

Efficacy and Safety Study of Pegasys plus lamivudin Vs lamivudine alone in the Treatment of Chronic Hepatitis B

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 24 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lamivudine (Primary) ; Peginterferon alfa-2a (Primary)
Indications Hepatitis B
Focus Adverse reactions; Therapeutic Use
Sponsors Roche

Most Recent Events

24 Sep 2020 Results published in the Internet Document
12 Sep 2020 Results (n=83) of retrospective NCT00048945 and other study evaluating Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B, published in the Journal of Hepatology
18 May 2018 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com